Email this article The clean and dirty ways to reduce suicidality
- Authors: Sivolap Y.P.1, Portnova A.A.2
-
Affiliations:
- I.M. Sechenov First Moscow State Medical University (Sechenov University)
- The Serbsky State Scientific Center for Social and Forensic Psychiatry
- Issue: Vol LIII, No 2 (2021)
- Pages: 18-25
- Section: Editorial
- URL: https://bakhtiniada.ru/1027-4898/article/view/71327
- DOI: https://doi.org/10.17816/nb71327
- ID: 71327
Cite item
Open Access
Access granted
Subscription Access
Abstract
Many psychiatric disorders, including depression, bipolar disorder, schizophrenia, and alcohol use disorder, are characterized by an increased suicidal risk. Successful treatment of mental disorders with the use of antidepressants, antipsychotics, and mood stabilizers can reduce the risk of associated suicidality: suicidal thoughts, suicide attempts, and completed suicides. Clozapine and lithium have an outstanding ability to reduce the probability of suicide, and their common property, which determines (along with other pharmacological effects) their antisuicidal potential, is the reduction of impulsivity and aggression. In addition to significant antisuicidal activity, clozapine and lithium are characterized by both an advantage in overall clinical efficacy over other drugs of their classes, and significant risk of side effects, as well as complications of therapy.
Full Text
##article.viewOnOriginalSite##About the authors
Yury P. Sivolap
I.M. Sechenov First Moscow State Medical University (Sechenov University)
Author for correspondence.
Email: yura-sivolap@yandex.ru
ORCID iD: 0000-0002-4494-149X
SPIN-code: 3586-5225
Scopus Author ID: 6604012934
Russian Federation, 119991, Moscow, Trubetskaya str., 8 (2)
Anna A. Portnova
The Serbsky State Scientific Center for Social and Forensic Psychiatry
Email: yura-sivolap@yandex.ru
ORCID iD: 0000-0001-5938-0202
SPIN-code: 5899-0069
Russian Federation, 119034, Moscow, Kropotkinsky Lane, 23 (1)
References
- Wasserman D., Carli V., Iosue M. et al. Suicide prevention in psychiatric patients. Asia. Pac. Psychiatry. 2021; e12450. doi: 10.1111/appy.12450. Online ahead of print.
- World Health Organization. Suicide in the world: Global health estimates (CC BY-NC-SA 3.0 IGO). Geneva, Switzerland. 2019. https://apps.who.int/iris/handle/10665/326948 (access date: 01.06.2021).
- Del Matto L., Muscas M., Murru A. et al. Lithium and suicide prevention in mood disorders and in the general population: A systematic review. Neurosci. Biobehav. Rev. 2020; 116: 142–153. doi: 10.1016/j.neubiorev.2020.06.017.
- Semple D., Smyth R. Oxford handbook of psychiatry. Fourth ed. Oxford: Oxford University Press. 2019; 1148 p.
- Lépine J.-P., Briley M. The increasing burden of depression. Neuropsychiatr. Dis. Treat. 2011; 7 (Suppl. 1): 3–7. doi: 10.2147/NDT.S19617.
- Bergfeld I.O., Mantione M., Figee M. et al. Treatment-resistant depression and suicidality. J. Affect. Disord. 2018; 235: 362–367. doi: 10.1016/j.jad.2018.04.016.
- Miller J.N., Black D.W. Bipolar disorder and suicide: A review. Curr. Psychiatry Rep. 2020; 22 (2): 6. doi: 10.1007/s11920-020-1130-0.
- Teobaldi E., Albert U., Di Salvo G. et al. Manic-depressive cycles in bipolar disorder: Clinical and treatment implications. Psychopathology. 2021; 54 (2): 98–105. doi: 10.1159/000513314.
- Meltzer H.Y., Alphs L., Green A.I. et al. Clozapine treatment for suicidality in schizophrenia: International Suicide Prevention Trial (InterSePT). Arch. Gen. Psychiatry. 2003; 60 (1): 82–91. doi: 10.1001/archpsyc.60.1.82.
- Patchan K.M., Richardson C., Vyas G., Kelly D.L. The risk of suicide after clozapine discontinuation: Cause for concern. Ann. Clin. Psychiatry. 2015; 27 (4): 253–256.
- Marcsisin M.J., Rosenstock J.B., Gannon J.M. Schizophrenia and related disorders. New York: Oxford University Press. 2017; 301 p.
- Meltzer H.Y. Suicidality in schizophrenia: a review of the evidence for risk factors and treatment options. Curr. Psychiatry. Rep. 2002; 4 (4): 279–283. doi: 10.1007/s11920-996-0047-6.
- Boenisch S., Bramesfeld A., Mergl R. et al. The role of alcohol use disorder and alcohol consumption in suicide attempts — а secondary analysis of 1921 suicide attempts. Eur. Psychiatry. 2010; 25 (7): 414–420. doi: 10.1016/j.eurpsy.2009.11.007.
- Shneidman E.S. Perspectives on suicidology. Further reflections on suicide and psychache. Suicide Life Threat. Behav. Fall. 1998; 28 (3): 245–250.
- Cummings M., Stahl S. Management of complex treatment-resistant psychotic disorders. Cambridge: Cambridge University Press. 2021; 304 p.
- Canuso C.M., Singh J.B., Fedgchin M. et al. Efficacy and safety of intranasal esketamine for the rapid reduction of symptoms of depression and suicidality in patients at imminent risk for suicide: Results of a double-blind, randomized, placebo-controlled study. Am. J. Psychiatry. 2018; 175 (7): 620–630. doi: 10.1176/appi.ajp.2018.17060720.
- Pompili M., Baldessarini R.J., Forte A. et al. Do atypical antipsychotics have antisuicidal effects? A hypothesis-generating overview. Int. J. Mol. Sci. 2016; 17 (10): 1700. doi: 10.3390/ijms17101700.
- Herings R.M., Erkens J.A. Increased suicide attempt rate among patients interrupting use of atypical antipsychotics. Pharmacoepidemiol. Drug. Saf. 2003; 12 (5): 423–424. doi: 10.1002/pds.837.
- Sharma V. Atypical antipsychotics and suicide in mood and anxiety disorders. Bipolar. Disord. 2003; 5 (Suppl. 2): 48–52. doi: 10.1111/j.1399-2406.2003.00062.x.
- Schatzberg A.F., DeBattista C. Schatzberg’s manual of clinical psychopharmacology. Ninth ed. Washington: American Psychiatric Association Publishing. 2019; 811 p.
- Hennen J., Baldessarini R.J. Suicidal risk during treatment with clozapine: A meta-analysis. Schizophr. Res. 2005; 73 (2–3): 139–145. doi: 10.1016/j.schres.2004.05.015.
- Freudenreich O. Psychotic disorders. A practical guide. Second ed. Arlington: Humana Press of Springer. 2020; 479 p.
- Taipale H., Lähteenvuo M., Tanskanen A. et al. Comparative effectiveness of antipsychotics for risk of attempted or completed suicide among persons with schizophrenia. Schizophr. Bull. 2021; 47 (1): 23–30. doi: 10.1093/schbul/sbaa111.
- Tiihonen J., Mittendorfer-Rutz E., Majak M. et al. Real-world effectiveness of antipsychotic treatments in a nationwide cohort of 29 823 patients with schizophrenia JAMA Psychiatry. 2017; 74 (7): 686–693. doi: 10.1001/jamapsychiatry.2017.1322.
- Frantz S. Drug discovery: playing dirty. Nature. 2005; 437 (7061): 942–943. doi: 10.1038/437942a.
Supplementary files
